Missouri Krantz, NP
Primary Care · la Junta, CONPI 1316495500
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 32.3% of the total. Reporting peaked in 2022 at $683 and has fallen 82.8% since, to $118 in 2025.
Across 99 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$502
- Novo Nordisk$236
- Lilly USA, LLC$124
- Pfizer$95
- Merck$80
- AstraZeneca$75
- plus $444 from 14 others
What the payments were for
- Food & beverage$1,54499%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $502 |
| Novo Nordisk | 17 | $236 |
| Lilly USA, LLC | 8 | $124 |
| Pfizer | 6 | $95 |
| Merck | 5 | $80 |
| AstraZeneca | 5 | $75 |
| Neurocrine Biosciences, Inc. | 4 | $66 |
| Amgen | 3 | $53 |
| Novartis | 3 | $47 |
| Exact Sciences | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Eisai Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Gilead | 1 | $15 |
How this compares
$1,556 in reported general payments places this provider in the 80th percentile of 112 primary care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $67,456 |
| OtezlaApremilast | 11 | $52,925 |
| JardianceEmpagliflozin | 24 | $30,416 |
| RybelsusSemaglutide | 13 | $25,386 |
| EliquisApixaban | 28 | $23,561 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $21,666 |
| TrulicityDulaglutide | 12 | $16,929 |
| MovantikNaloxegol Oxalate | 18 | $8,065 |
| CreonLipase/Protease/Amylase | 11 | $5,391 |
| Celecoxib | 23 | $2,147 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 58 | $1,826 |
| Levothyroxine Sodium | 148 | $1,543 |
| Gabapentin | 78 | $1,352 |
| Atorvastatin Calcium | 139 | $1,217 |
| Omeprazole | 80 | $1,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $236 | $92,84257 claims |
| AmgenOtezla | $53 | $52,92511 claims |
| Boehringer IngelheimJardiance | $16 | $30,41624 claims |
| PfizerEliquis | $95 | $23,56128 claims |
| AstraZenecaBreztri Aerosphere | $75 | $21,66628 claims |
| Lilly USA, LLCTrulicity | $124 | $16,92912 claims |
| AbbVieCreon | $502 | $5,39111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 primary care providers in Colorado.
Other primary care in la Junta
- Caitlin Philpyla Junta$2K
- Laura CarlsenLittleton$22K
- Kendra PayneCastle Rock$22K
- Kaitlin KrausDenver$16K
- Emily WillmannThornton$4K
- Tracy RasmussenParker$4K
- Linda MyersGrand Junction$4K
- Kathryn PalmerGreeley$4K
- Leah BrownFort Morgan$3K
- Diana Rodriguez OrtizAurora$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.